Fertility and Sterility
Volume 91, Issue 4, Supplement , Pages 1366-1369 , April 2009

GnRH analogue for the prevention of ovarian hyperstimulation syndrome: a pilot study

  • Juan Giles, M.D.

      Affiliations

    • IVI Madrid, Calle Santiago de Compostela 88, Madrid, Spain
    • Corresponding Author InformationReprint requests: Juan Giles, M.D., IVI Madrid, Unidad de Reproducción, C/Santiago de Compostela 88, Madrid 28035, Spain (FAX: 34-913867133).
    • ,
  • Antonio Requena, M.D.

      Affiliations

    • IVI Madrid, Calle Santiago de Compostela 88, Madrid, Spain
    • ,
  • Juan Antonio García-Velasco, M.D.

      Affiliations

    • IVI Madrid, Calle Santiago de Compostela 88, Madrid, Spain
    • ,
  • Alberto Pacheco, Ph.D.

      Affiliations

    • IVI Madrid, Calle Santiago de Compostela 88, Madrid, Spain
    • ,
  • Jorge Pellicer, Ph.D.

      Affiliations

    • IVI Madrid, Calle Santiago de Compostela 88, Madrid, Spain
    • ,
  • Antonio Pellicer, M.D.

      Affiliations

    • IVI Valencia, Plaza Policia Local 3, Valencia, Spain

Received 16 December 2006 ,Revised 9 April 2008 ,Accepted 9 April 2008.

References 

  1. The Practice Committee of the American Society for Reproductive Medicine. Ovarian hyperstimulation syndrome. Fertil Steril. 2003;80:1309–1314
  2. Levy T, Orvieto R, Homburg R, Peleg D, Dekel A, Ben-Rafael Z. Severe ovarian hyperstimulation syndrome despite low plasma oestrogen concentrations in a hypogonadotrophic, hypogonadal patient. Hum Reprod. 1996;11:1177–1179
  3. Cluroe AD, Synek BJ. A fatal case of ovarian hyperstimulation syndrome with cerebral infarction. Pathology. 1995;27:344–346
  4. Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohi J, Simon C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril. 1999;71:482–489
  5. Lee A, Christenson LK, Stouffer RL, Burry KA, Patton PE. Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. Fertil Steril. 1997;68:305–311
  6. Artini PG, Fasciani A, Monti M, Luisi S, D'Ambrogio G, Genazzani AR. Changes in vascular endothelial growth factor levels and the risk of ovarian hyperstimulation syndrome in women enrolled in an in vitro fertilization program. Fertil Steril. 1998;70:560–564
  7. Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril. 1997;67:261–265
  8. Agrawal R, Tan SL, Wild S, Sladkevicius P, Engmann L, Payne N, et al. Serum vascular endothelial growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation síndrome. Fertil Steril. 1999;71:287–293
  9. Albert C, Garrido N, Mercader A, Rao CV, Remohi J, Simon C, et al. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Mol Hum Reprod. 2002;8:409–418
  10. Pau E, Alonso-Muriel I, Gómez R, Novella E, Ruiz A, García-Velasco JA, et al. Plasma levels of soluble vascular endothelial growth factor receptor-1 may determine the onset of early and late ovarian hyperstimulation syndrome. Hum Reprod. 2006;21:1453–1460
  11. Garcia-Velasco JA, Zuniga A, Pacheco A, Gomez R, Simon C, Pellicer A. Coasting acts through downregulation of VEGF gene expression and protein secretion. Hum Reprod. 2004;19:1530–1538
  12. Tozer AJ, Iles RK, Iammarrone E, Gillott CM, Al-Shawaf T, Grudzinskas JG. The effects of “coasting” on follicular fluid concentrations of vascular endothelial growth factor in women at risk of developing ovarian hyperstimulation syndrome. Hum Reprod. 2004;19:522–528
  13. Gómez R, Simón C, Remohí J, Pellicer A. Vascular endothelial growth factor receptor-2 activation induces vascular permeability in hyperstimulated rats, and this effect is prevented by receptor blockade. Endocrinology. 2002;143:4339–4348
  14. Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, Novella-Maestre E, Alonso-Muriel I, Sanchez-Criado J. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinology. 2006;147:5400–5411
  15. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, et al. Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab. 2007;92:2931–2937
  16. Pellicer A, Albert C, Mercader A, Bonilla-Musoles F, Remohí J, Simón C. The pathogenesis of ovarian hyperstimulation syndrome: in vivo studies investigating the role of interleukin-1beta, interleukin-6, and vascular endothelial growth factor. Fertil Steril. 1999;71:482–489
  17. Aboulghar MA, Mansour RT, Serour GI, El Helw BA, Shaarawy M. Elevated levels of interleukin-2, soluble interleukin-2 receptor alpha, interleukin-6, soluble interleukin-6 receptor and vascular endothelial growth factor in serum and ascitic fluid of patients with severe ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol. 1999;87:81–85
  18. Rizk B, Aboulghar M, Smitz J, Ron-El R. The role of vascular endothelial growth factor and interleukins in the pathogenesis of severe ovarian hyperstimulation syndrome. Hum Reprod Update. 1997;3:255–266
  19. Soares SR, Troncoso C, Bosch E, Serra V, Simón C, Remohí J, et al. Age and uterine receptiveness: predicting the outcome of oocyte donation cycles. J Clin Endocrinol Metab. 2005;90:4399–4404
  20. Orvieto R. Prediction of ovarian hyperstimulation syndrome. Challenging the estradiol mythos. Hum Reprod. 2003;18:665–667
  21. Chenette PE, Sauer MV, Paulson RJ. Very high serum estradiol levels are not detrimental to clinical outcome of in vitro fertilization. Fertil Steril. 1990;54:858–863
  22. Wada I, Matson PL, Horne G, Buck P, Lieberman BA. Is continuation of a gonadotrophin-releasing hormone agonist (GnRHa) necessary for women at risk of developing the ovarian hyperstimulation syndrome?. Hum Reprod. 1992;7:1090–1093
  23. Endo T, Honnma H, Hayashi T, Chida M, Yamazaki , Kitajima Y, et al. Continuation of GnRH agonist administration for 1 week, after HCG injection, prevents ovarian hyperstimulation syndrome following elective cryopreservation of all pronucleate embryos. Hum Reprod. 2002;17:2548–2551
  24. Nikolettos N, Asimakopoulos B, Simopoulou M, al-Hasani S. GnRH agonist administration after embryo transfer, in long protocol stimulated cycles, prevents ovarian hyperstimulation syndrome. A report of five cases. In Vivo. 2003;17:655–658
  25. Olivennes F, Cunha-Filho JS, Fanchin R, Bouchard P, Frydman R. The use of GnRH antagonists in ovarian stimulation. Hum Reprod Update. 2002;8:279–290
  26. The European Orgalutran Study GroupBorm G, Mannaerts B. Treatment with the gonadotrophin- releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre. Hum Reprod. 2000;15:1490–1498
  27. Coccia ME, Comparetto C, Bracco GL, Scarselli G. GnRH antagonists. Eur J Obstet Gynecol Reprod Biol. 2004;115(Suppl 1):S44–S56
  28. de Jong D, Macklon NS, Mannaerts BM, Coelingh Bennink HJ, Fauser BC. High dose gonadotrophin-releasing hormone antagonist (ganirelix) may prevent ovarian hyperstimulation syndrome caused by ovarian stimulation for in-vitro fertilization. Hum Reprod. 1998;13:573–575
  29. Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, Kolibianakis EM. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist. Reprod Biomed Online. 2007;15:408–412
  30. Kitajima Y, Endo T, Henmi H, et al. Gonadotropin-releasing hormone agonist suppress the expression of vascular endothelial growth factor and its receptors messenger ribonucleic acid in newly formed corpora lutea of superovulated rats. Biol Reprod. 1998;58(Suppl 1):107
  31. Goto T, Endo T, Henmi H, Kitajima Y, Kiya T, Nishikawa A, et al. Gonadotropin-releasing hormone agonist has the ability to induce increased matrix metalloproteinase (MMP)-2 and membrane type 1-MMP expression in corpora lutea, and structural luteolysis in rats. J Endocrinol. 1999;161:393–402
  32. Fridén BE, Nilsson L. Gonadotrophin-releasing hormone-antagonist luteolysis during the preceding mid-luteal phase is a feasible protocol in ovarian hyperstimulation before in vitro fertilization. Acta Obstet Gynecol Scand. 2005;84:812–816
  33. Kitajima Y, Endo T, Manase K, Nishikawa A, Shibuya M, Kudo R. Gonadotropin-releasing hormone agonist administration reduced vascular endothelial growth factor (VEGF), VEGF receptors, and vascular permeability of the ovaries of hyperstimulated rats. Fertil Steril. 2004;81(Suppl 1):842–849
  34. Taylor PD, Hillier SG, Fraser HM. Effects of GnRH antagonist treatment on follicular development and angiogenesis in the primate ovary. J Endocrinol. 2004;183:1–17
  35. Harwood JP, Clayton RN, Catt KJ. 1980. Ovarian gonadotropin-releasing hormone receptors. I. Properties and inhibition of luteal cell function. Endocrinology. 1980;107:407–413
  36. Harwood JP, Clayton RN, Chen TT, Knox G, Catt KJ. Ovarian gonadotropin-releasing hormone receptors. II. Regulation and effects on ovarian development. Endocrinology. 1980;107:414–421

 J.G. has nothing to disclose. A.R. has nothing to disclose. J.A.G-V. has nothing to disclose. A. Pacheco has nothing to disclose. J.P. has nothing to disclose. A. Pellicer has nothing to disclose.

PII: S0015-0282(08)00880-7

doi: 10.1016/j.fertnstert.2008.04.017

Fertility and Sterility
Volume 91, Issue 4, Supplement , Pages 1366-1369 , April 2009

Article Tools